Johnson & Johnson (JNJ) Restructuring Costs (2010 - 2026)
Johnson & Johnson (JNJ) posted Restructuring Costs of $34.0 million for Q2 2026, up 6.25% sequentially from $32.0 million in Q1 2026, and down 46.88% YoY from $64.0 million in Q2 2025.
Johnson & Johnson (JNJ) Restructuring Costs (2010 - 2026) Analysis & Trends
Johnson & Johnson has reported Restructuring Costs for 14 years, with the latest figure at $34.0 million in Q2 2026.
- Quarterly Restructuring Costs fell 46.88% year-over-year to $34.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $213.0 million (up 29.88% YoY) and the FY2025 annual result came in at $228.0 million, down 2.56% from the prior year.
- Restructuring Costs grew to $34.0 million in Q2 2026 per JNJ's latest filing, from $32.0 million in the prior quarter.
- Over five years, Restructuring Costs peaked at $164.0 million in Q1 2024 and troughed at -$13.0 million in Q2 2024.
- A 5-year average of $74.6 million and a median of $64.5 million in 2022 frame the typical range for Restructuring Costs.
- The sharpest annual moves came in 2024 and 2025: Restructuring Costs tumbled 108.97% in 2024, then soared 592.31% in 2025.
- Over 5 years, Restructuring Costs stood at $65.0 million in 2022, then slipped by 13.85% to $56.0 million in 2023, then retreated by 25.0% to $42.0 million in 2024, then surged by 100.0% to $84.0 million in 2025, then tumbled by 59.52% to $34.0 million in 2026.
- According to Business Quant data, Restructuring Costs over the past three periods registered $34.0 million, $32.0 million, and $84.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 34.00 Mn |
| Mar 29, 2026 | 32.00 Mn |
| Dec 28, 2025 | 84.00 Mn |
| Sep 28, 2025 | 63.00 Mn |
| Jun 29, 2025 | 64.00 Mn |
| Mar 30, 2025 | 17.00 Mn |
| Dec 29, 2024 | 42.00 Mn |
| Sep 29, 2024 | 41.00 Mn |
| Jun 30, 2024 | -13.00 Mn |
| Mar 31, 2024 | 164.00 Mn |
| Dec 31, 2023 | 56.00 Mn |
| Oct 1, 2023 | 158.00 Mn |
| Jul 2, 2023 | 145.00 Mn |
| Apr 2, 2023 | 130.00 Mn |
| Jan 1, 2023 | 106.00 Mn |
| Oct 2, 2022 | 65.00 Mn |
| Jul 3, 2022 | 85.00 Mn |
| Apr 3, 2022 | 70.00 Mn |
| Oct 3, 2021 | 60.00 Mn |
| Jul 4, 2021 | 56.00 Mn |